[go: up one dir, main page]

MX2010009628A - Formulaciones liquidas estables de agentes antiinfecciosos, y regimenes de dosificacion ajustados de los agentes antiinfecciosos. - Google Patents

Formulaciones liquidas estables de agentes antiinfecciosos, y regimenes de dosificacion ajustados de los agentes antiinfecciosos.

Info

Publication number
MX2010009628A
MX2010009628A MX2010009628A MX2010009628A MX2010009628A MX 2010009628 A MX2010009628 A MX 2010009628A MX 2010009628 A MX2010009628 A MX 2010009628A MX 2010009628 A MX2010009628 A MX 2010009628A MX 2010009628 A MX2010009628 A MX 2010009628A
Authority
MX
Mexico
Prior art keywords
infective
liquid formulations
stable liquid
dosing regimens
adjusted
Prior art date
Application number
MX2010009628A
Other languages
English (en)
Inventor
Gary Liversidge
Original Assignee
Elan Pharma Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharma Int Ltd filed Critical Elan Pharma Int Ltd
Publication of MX2010009628A publication Critical patent/MX2010009628A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proveen métodos para determinar un régimen de dosificación ajustado a la resistencia, de un agente antiinfeccioso para el tratamiento de una infección de un mamífero por un organismo infeccioso resistente, en donde se conoce un régimen de dosificación efectivo del agente antiinfeccioso para el tratamiento de una infección del mamífero por una cepa susceptible del organismo infeccioso; se proveen también métodos de tratamiento de una infección bacteriana resistente a cefepima en un paciente.
MX2010009628A 2008-03-04 2009-03-03 Formulaciones liquidas estables de agentes antiinfecciosos, y regimenes de dosificacion ajustados de los agentes antiinfecciosos. MX2010009628A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3359808P 2008-03-04 2008-03-04
PCT/US2009/035794 WO2009111422A2 (en) 2008-03-04 2009-03-03 Stable liquid formulations of anti-infective agents and adjusted anti-infective agent dosing regimens

Publications (1)

Publication Number Publication Date
MX2010009628A true MX2010009628A (es) 2010-09-28

Family

ID=41054292

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010009628A MX2010009628A (es) 2008-03-04 2009-03-03 Formulaciones liquidas estables de agentes antiinfecciosos, y regimenes de dosificacion ajustados de los agentes antiinfecciosos.

Country Status (12)

Country Link
US (2) US20090227554A1 (es)
EP (1) EP2257159A4 (es)
JP (1) JP2011514902A (es)
KR (1) KR20100137439A (es)
AU (1) AU2009222020A1 (es)
CA (1) CA2713989A1 (es)
IL (1) IL207968A0 (es)
MX (1) MX2010009628A (es)
NO (1) NO20101375L (es)
TW (1) TW200940552A (es)
WO (1) WO2009111422A2 (es)
ZA (1) ZA201005495B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2970338A1 (en) 2013-03-14 2016-01-20 Merck Sharp & Dohme Corp. Crystalline form of a beta-lactamase inhibitor
US9872906B2 (en) 2013-03-15 2018-01-23 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
US20140274990A1 (en) 2013-03-15 2014-09-18 Cubist Pharmaceuticals, Inc. Ceftolozane pharmaceutical compositions
DK2893929T3 (da) * 2013-03-15 2025-07-07 Merck Sharp & Dohme Llc Antibiotisk ceftolozansammensætninger
AU2014233637A1 (en) 2013-09-09 2015-03-26 Merck Sharp & Dohme Corp. Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
US8906898B1 (en) 2013-09-27 2014-12-09 Calixa Therapeutics, Inc. Solid forms of ceftolozane
WO2015051101A1 (en) 2013-10-02 2015-04-09 Cubist Pharmaceuticals, Inc. B-lactamase inhibitor picoline salt
AU2017242134B2 (en) * 2016-03-31 2022-12-01 Wockhardt Limited Antibacterial compositions
CN107847501A (zh) * 2016-03-31 2018-03-27 沃克哈特有限公司 抗菌组合物以及方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL203689B1 (pl) * 1998-09-25 2009-11-30 Cubist Pharmaceuticals Zastosowanie daptomycyny
JP2002543434A (ja) * 1999-04-29 2002-12-17 デイド マイクロスキャン インコーポレーテッド 迅速な抗菌物質感受性アッセイと微生物同定を組み合わせたシステム
US6884791B2 (en) * 1999-07-06 2005-04-26 Methylgene, Inc. Inhibitors of β-lactamase
US6482982B1 (en) * 2001-03-09 2002-11-19 University Of Sciences Of Philadelphia Halogenated antituberculosis agents
JP2005538183A (ja) * 2001-09-13 2005-12-15 ジーンソフト ファーマシューティカルズ インコーポレイテッド 薬剤耐性細菌による感染症の治療方法
US7378408B2 (en) * 2001-11-30 2008-05-27 Pfizer Inc. Methods of treatment and formulations of cephalosporin
US20030152515A1 (en) * 2002-02-06 2003-08-14 Ren-Jin Lee Method for estimating effective regimens and patient survival rates of antibiotic treatments for fatal infectious diseases
CN101785830A (zh) * 2002-06-13 2010-07-28 株式会社凤凰堂 抗菌剂和抗菌性组合物
AU2003241675A1 (en) * 2002-06-21 2004-01-06 Shionogi And Co., Ltd. Medicinal cephem compound composition for injection
US7244712B2 (en) * 2003-03-14 2007-07-17 President And Fellows Of Harvard College Aminoglycoside antibiotics and methods of using same
US20060018966A1 (en) * 2003-07-22 2006-01-26 Lin Victor S Antimicrobial mesoporous silica nanoparticles
WO2005041978A1 (en) * 2003-10-21 2005-05-12 Johns Hopkins University Neuroprotection with beta-lactam compounds
CA2559208A1 (en) * 2004-03-17 2005-09-29 Mpex Pharmaceuticals, Inc. Use and administration of bacterial efflux pump inhibitors
WO2005094800A2 (en) * 2004-03-31 2005-10-13 Lupin Ltd. A co-precipitated cefepime composition and process for preparation thereof
EP1656930A1 (en) * 2004-11-10 2006-05-17 Basilea Pharmaceutica AG Stabilized freeze-dried formulation for cephalosporin derivatives
US20070231335A1 (en) * 2005-07-20 2007-10-04 Bruce Beutler Compositions and methods for treating Gram positive bacterial infection in a mammalian subject
ES2594368T3 (es) * 2005-12-08 2016-12-19 Insmed Incorporated Composiciones a base de lípidos de antiinfecciosos para tratar infecciones pulmonares
EP2004674B1 (en) * 2006-03-23 2013-02-20 Agriculture Victoria Services Pty Ltd Antimicrobial protein
US20090048160A1 (en) * 2007-08-17 2009-02-19 Bannerman Douglas D Antimicrobial activity of bovine bactericidal/permeability-increasing protein (BPI)-derived peptides against Gram-negative bacterial mastitis isolates
EP2217614A4 (en) * 2007-11-07 2011-12-07 Dynamic Microbials Ltd ANTIMICROBIAL COMPOSITIONS, FORMULATIONS AND APPLICATIONS THEREOF

Also Published As

Publication number Publication date
JP2011514902A (ja) 2011-05-12
WO2009111422A3 (en) 2009-12-30
US20090227554A1 (en) 2009-09-10
WO2009111422A2 (en) 2009-09-11
KR20100137439A (ko) 2010-12-30
NO20101375L (no) 2010-10-04
AU2009222020A1 (en) 2009-09-11
CA2713989A1 (en) 2009-09-11
ZA201005495B (en) 2011-04-28
EP2257159A2 (en) 2010-12-08
US20120115836A1 (en) 2012-05-10
IL207968A0 (en) 2010-12-30
WO2009111422A9 (en) 2010-04-15
EP2257159A4 (en) 2011-05-11
TW200940552A (en) 2009-10-01

Similar Documents

Publication Publication Date Title
MX2010009628A (es) Formulaciones liquidas estables de agentes antiinfecciosos, y regimenes de dosificacion ajustados de los agentes antiinfecciosos.
MY204500A (en) Dosing regimen associated with long acting injectable paliperidone esters
MX2013010770A (es) Tratamiento de tumores solidos.
TN2012000335A1 (en) Antibody formulation and therapeutic regimens
GEP201706786B (en) Methods and drug products for treating alzheimer's disease
NZ717373A (en) The use of inhibitors of bruton’s tyrosine kinase (btk)
NZ701715A (en) Means and methods for treating dlbcl
GEP20166455B (en) Methods of administering pirfenidone therapy
IN2012DN06309A (es)
MX2011013296A (es) Metodos de tratamiento o prevención de enfermedad asociada a influenza con soluciones acuosas con potencial de oxidación-reduccion.
MX2011007195A (es) Derivado de ciclosporina para el uso en el tratamiento de infección de virus de hepatitis c (vhc) y virus de inmunodeficiencia humana (vih).
EA201490378A1 (ru) ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β
ITFI20110166A1 (it) Nuovi fotosensibilizzanti ad uso terapeutico.
WO2012174224A3 (en) Methods for administering nucleic acid-based therapeutics
WO2012063134A3 (en) Cardiac glycoside analogs in combination with emodin for cancer therapy
NZ591525A (en) Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin
MX2009006574A (es) Tratamiento de cancer de pulmon.
NO20091580L (no) Behandling av infant-hyperbilirubinemi ved anvendelse av lave doser stannsoporfin
RU2013104381A (ru) Лечение отслойки васкуляризированного пигментного эпителия терапевтическим средством против vegf
MX2013003903A (es) Nuevos tratamientos de infeccion por el virus de hepatitis c.
UA109944U (uk) Фармацевтична композиція для зниження рівня n-оксиду триметиламіну
UA99163C2 (ru) Способ дозирования инъекционной формы палиперидона пальмитата продолжительного действия
TNSN06305A1 (en) Treatment regimen for camptothecin derivatives
UA56131U (ru) Способ применения специфического иммуноглобулина против граммотрицательных бактерий для лечения сепсиса и тяжелых инфекций
An A Case Study on the Bartholin's Duct Abscess treated by DahuangMudan-Tang

Legal Events

Date Code Title Description
FA Abandonment or withdrawal